Albumin is a concentrate of plasma proteins from blood and it works by increasing plasma volume or serum albumin levels. Albumin is used in treating a variety of conditions, including shock due to blood loss in the body, burns, low protein levels due to surgery or liver failure, and as an additional medicine in bypass surgery. Albumin as an excipient has wide applications in drug formulation, drug delivery, vaccine manufacturing and as a component of media for the production of vaccines. It is widely used in pharmaceutical and biotechnology products. Most of the albumin used as an excipient is either derived from plasma or produced from recombinant technology.
The global albumin market segmentation is based on type (human serum albumin, bovine serum albumin, recombinant albumin), and its applications (drug formulation and drug delivery, vaccines, components of media). The global albumin market report provides market size (Revenue US$ Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global albumin market segmentation is based on geography (regional and country based). The global albumin market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global albumin market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in this market include CSL Behring, HiMedia Laboratories Pvt. Ltd., InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc. and MedxBio Pte. Ltd.